Vaccine therapy for men with rising PSA or new bone lesions or enlarging soft tissue mass following treatment with hormone therapy for prostate cancer.
Participants qualify if between 18-85 years of age with a testosterone level less than 50. PSA has to have risen at least two times or there is evidence of a new bone lesion. Participants must have had a previous small pox vaccination.
Exclusions include, but are not limited to: Prior Taxotere treatment, splenectomy or immunodeficiency, inflammatory eye disease, prior Provenge treatment, active skin disease, atopic dermatitis and an egg or Gentamycin allergy.
Clinical Trial # S1216:
Androgen deprivation with Casodex or TAK-700 for men with newly diagnosed metastatic, hormone sensitive disease.
Participants must have a PSA of 2 or greater and soft tissue AND/OR bone metastases. Prior neo-adjuvant or adjuvant treatment is allowed if it was greater than 2 years ago. Prior palliative radiation is allowed. Patients may currently be on bisphosphonates.
Exclusions include, but are not limited to: Brain metastases, uncontrolled hypertension, bilateral orchiectomy, adrenal insufficiency, HIV, HEP B and HEP C.
Clinical Trial # 11785:
Second line treatment with Cabazitaxel/Prednisone for hormone resistant disease.
Participants may have been previously treated with Taxotere.
Participants must have had progression of disease during or after treatment indicated by either a rising PSA or measurable disease.
Exclusions include, but are not limited to: Previous treatment of Mitoxantron, prior radiation therapy involving more that 30% of their bone marrow or any uncontrolled cardiac conditions.
Clinical Trial #70807:
Participants must have a clinical stage of less than or equal to T2a and have chosen active surveillance. This trial collects data with respects to dietary intervention versus unchanged diet.
Participants must be 50-80 years of age with less than 25% positive cores from biopsy.
Participants equal to or under the age of 70 are required to have a gleason score no higher than 6.
Participants over the age of 70 are required to have a gleason score no higher than 7.
Exclusions include, but are not limited to: prior radiation, surgery or androgen deprivation and must not be currently consuming six (6) or more fruits or vegetables daily.
Clinical Trial #13387-04:
Trial drug 13387-04 with or without Abiraterone (Zytiga) for patients who have progressed on Abiraterone (Zytiga) alone.
Progression is defined as three consecutive increases in PSA value or two or more new bone lesions or increased soft tissue disease.
Participants must have received at least one month of Abirateron (Zytiga).
Exclusions include, but are not limited to: Surgery or radiation therapy in the last four weeks, prior dose reductions of Abiraterone (Zytiga), metastatic disease to the central nervous system or a left ventricle ejection fraction of less than 50%.
